Assistant Professor, Oncology, University of Texas Medical School at Houston
Hematology
Dr. Gautam Borthakur, MD
|
|
Give Review
Gautam Borthakur works in the field of Hematology. He went to medical school at Assam Medical College. He has 1 awards "Top Doctors:SE Texas". Gautam Borthakur is a published doctor and has 102 publications published. The lastest was: 'Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.' Gautam Borthakur accepts all Medicare patients.
Publications
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
- Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal ...
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Analysis of 2013 European LeukaemiaNet (ELN) responses in Chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
- Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
- Improvement in clinical outcome of FLT3 ITD mutated Acute myeloid leukemia patients over the last one and a half decade.
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
- Estimated glomerular filtration rate changes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors.
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed Acute myeloid leukemia.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in Acute myeloid ...
- RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with Acute myeloid leukaemia inv(16) subtype.
- Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia.
- A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia.
- Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with Acute myeloid leukemia and myelodysplastic syndrome.
- Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory Acute lymphocytic leukaemia.
- Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory Acute lymphoblastic leukemia.
- REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated Acute myeloid leukaemia.
- Clinical characteristics and outcomes in patients with Acute promyelocytic leukaemia and hyperleucocytosis.
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and Acute myelogenous leukemia.
- A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acut...
- A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia.
- Treatment with FLT3 inhibitor in patients with FLT3-mutated Acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
- Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum, and Blastoschizomyces capitatus) in a patient with Acute myeloid leukemia.
- Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies.
- Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome.
- A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with Acute myeloid leukemia treated with hypomethylating agents.
- Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with Acute myeloid leukemia.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics.
- Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
- Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia.
- The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell Acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson c...
- HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid Leukemia.
- Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic Syndrome is associated with poor prognosis and transformation to acut...
- Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tand...
- Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials.
- Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy.
- Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia.
- Significance of deeper molecular responses in patients with chronic myeloid Leukemia in early chronic phase treated with tyrosine kinase inhibitors.
- Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia.
- Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome.
- Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed Acute myeloid leukemia (AML).
- XIAP antisense therapy with AEG 35156 in Acute myeloid leukemia.
- Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities.
- Phase II study of azacytidine plus sorafenib in patients with Acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
- Lenalidomide as a novel treatment of Acute myeloid leukemia.
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced Myeloid malig...
- Prognostic impact of RAS mutations in patients with myelodysplastic Syndrome.
- Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary Acute myeloid leukemia.
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed Acute myeloid leukemia.
- Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
- Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results.
- Clinical and proteomic characterization of Acute myeloid leukemia with mutated RAS.
- A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities.
- Predicting survival of patients with hypocellular myelodysplastic Syndrome: development of a disease-specific prognostic score system.
- Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with Acute myeloid leukemia.
- A randomized study of decitabine versus conventional care for maintenance therapy in patients with Acute myeloid leukemia in complete remission.
- Phase I-II study of bendamustine in patients with Acute leukemia and high risk myelodysplastic syndrome.
- Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype Acute myelogenous leukemia.
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm Acute myeloid leukemia.
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
- Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplast...
- Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High...
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
- Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting ...
- Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Revie...
- A single case of rosai-dorfman Disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine.
- A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia.
- Extramedullary Acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature.
- A prognostic score for patients with lower risk myelodysplastic Syndrome.
- Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic Anemia and myelodysplastic syndrome.
- Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in Acute myeloid leukemia patients.
- Adult Acute erythroleukemia: an analysis of 91 patients treated at a single institution.
- Malignant rhabdoid tumour of kidney. A case report.
- Sulfatides inhibit platelet adhesion to von Willebrand factor in flowing blood.
- Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation.
- Characteristics of translocation (16;16)(p13;q22) Acute myeloid leukemia.
- Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic Syndrome.
- Hypocellular Acute myeloid leukemia in adults: clinical outcome analysis of 123 patients.
- Prediction of early death after induction therapy for newly diagnosed Acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
- Implications of discrepancy in morphologic diagnosis of myelodysplastic Syndrome between referral and tertiary care centers.
- Pronounced hypoxia in models of murine and human Leukemia: high efficacy of hypoxia-activated prodrug PR-104.
- The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid Leukemia after failure to front-line the...
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
- Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid Leukemia in chronic or accelerated phase.
- A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic Syndrome.
- Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid Leukemia.
- Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed Acute myeloid leukemia.
- Clofarabine: emerging role in Leukemias.
- The heterogeneous prognosis of patients with myelodysplastic Syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
- Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or pri...
- Long-term outcome of patients with chronic myeloid Leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vit...
- Chronic myeloid Leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
- Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid Leukemia in chronic phase after imatinib failure.
- Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory Myeloid malignancies.
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors:SE Texas
Education
-
University of Texas Health Science Center -
Brooklyn Hospital Center -
Assam Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1629177944 | |
| NPPES Provider LastName | BORTHAKUR | |
| NPPES Provider FirstName | GAUTAM | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 610.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 2.46 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629177944 |
| Last Name Of The Provider | BORTHAKUR |
| First Name Of The Provider | GAUTAM |
| View All |
Similar Doctors
|
|
Dr. William G. Wierda, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Giuseppe Fraschini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Ludwig IV, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shylashree C. Chikkamuniyappa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Effrosyni Apostolidou, MD |
|
|
Dr. Jun Zhang, MD |
|
|
Dr. Jennifer Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheridan M. Diaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vahid Afsharkharghan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jan A. Burger, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Guiying Hu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brittany K. Ragon, MD |
|
|
Dr. Xiaohong I. Wang, MD |